Edgestream Partners L.P. Has $2.87 Million Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Edgestream Partners L.P. boosted its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 82.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 99,401 shares of the company’s stock after buying an additional 44,829 shares during the quarter. Edgestream Partners L.P. owned approximately 0.08% of Apellis Pharmaceuticals worth $2,867,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Braidwell LP increased its position in Apellis Pharmaceuticals by 410.8% during the third quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after buying an additional 2,513,383 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Apellis Pharmaceuticals by 191.9% during the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock worth $61,845,000 after buying an additional 1,409,707 shares during the last quarter. Fiera Capital Corp increased its position in Apellis Pharmaceuticals by 47.7% during the second quarter. Fiera Capital Corp now owns 1,401,190 shares of the company’s stock worth $53,750,000 after buying an additional 452,753 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Apellis Pharmaceuticals by 1.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 956,362 shares of the company’s stock worth $27,581,000 after buying an additional 9,328 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in Apellis Pharmaceuticals by 6.9% during the second quarter. Bank of New York Mellon Corp now owns 345,195 shares of the company’s stock worth $13,242,000 after buying an additional 22,273 shares during the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insider Buying and Selling

In other news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $36.23, for a total value of $1,340,510.00. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $3,623,000. This trade represents a 27.01 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 6.80% of the stock is owned by corporate insiders.

Apellis Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:APLS opened at $33.93 on Monday. The firm has a market cap of $4.22 billion, a P/E ratio of -16.71 and a beta of 0.87. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 12-month low of $24.34 and a 12-month high of $73.80. The business has a fifty day simple moving average of $28.72 and a 200 day simple moving average of $35.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million for the quarter, compared to the consensus estimate of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue for the quarter was up 78.3% on a year-over-year basis. During the same period in the prior year, the business earned ($1.17) earnings per share. Analysts predict that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Wall Street Analyst Weigh In

APLS has been the topic of a number of recent analyst reports. Wedbush boosted their price target on Apellis Pharmaceuticals from $38.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. The Goldman Sachs Group reduced their price objective on Apellis Pharmaceuticals from $71.00 to $36.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. UBS Group reduced their price objective on Apellis Pharmaceuticals from $85.00 to $83.00 and set a “buy” rating for the company in a report on Friday, August 9th. Bank of America reduced their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Finally, Wells Fargo & Company reduced their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.94.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).